Silver Creek Pharmaceuticals, a San Francisco-based clinical-stage biotechnology company, announced on Monday that it has named Mark Corrigan, MD as its new president.

Dr Corrigan has more than three decades of life sciences leadership and drug development experience. He has most recently served as CEO of Tremeau Pharmaceuticals. He has worked as CEO of Correvio Pharma Corp and executive vice president, Research and Development, at Sepracor. He has served for 10 years with Pharmacia & Upjohn, concluding as vice president of Global Clinical Research and Experimental Medicine. He has worked as chairman of the board of Elios Therapeutics and as a member of the board of Wave Life Sciences and Trevena Pharmaceuticals. He has previously served on the board of Cubist prior to its acquisition by Merck and on the board of Avanir prior to its acquisition by Otsuka.

Tim Throsby, Silver Creek's chairman of the board, said, 'We are pleased to welcome Dr Corrigan to lead Silver Creek through its next phase of growth. We are confident that Mark's deep experience in drug development and life sciences leadership will enable the company to continue to advance scp776 and our Smart Growth Factor platform, bringing us one step closer to achieving our mission of changing lives by rescuing cells from injury.'